newsfilter
← Latest News
GlobeNewswire·

Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache

Study Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief Exploratory Patient-Reported Outcomes Data Indicated More Than One Third of Patients Experienced Pain Freedom and Two Thirds Had Pain Relief Two Hours Following